Functionality of chimeric E2 glycoproteins of BVDV and CSFV in virus replication by Gennip, H.G.P., van et al.
Virology: Research and Treatment 2008:1 29–40 29
ORIGINAL RESEARCH
Correspondence: H.G.P. van Gennip, Central Veterinary Institute of (CVI) of Wageningen UR, 
Department of Virology, Department of Mammalian Virology, P.O. Box 2004, 8203 AA Lelystad, The 
Netherlands. Tel: +31 320 238238; Fax: +31 320 238668; Email: rene.vangennip@wur.nl
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Functionality of Chimeric E2 Glycoproteins of BVDV 
and CSFV in Virus Replication
H.G.P. van Gennip, G.K.W Miedema, R.J.M. Moormann and P.A van Rijn
Central Veterinary Institute of (CVI) of Wageningen UR, P.O. Box 2004, 8203 AA Lelystad, The 
Netherlands.
Abstract: An intriguing difference between the E2 glycoprotein of CSFV and the other groups of pestiviruses (nonCSFV) 
is a lack of two cysteine residues on positions cysteine 751 and 798. Other groups of pestivirus are not restricted to one 
species as swine, whereas CSFV is restricted to swine and wild boar. We constructed chimeric CSFV/BVDV E2 genes based 
on a 2D model of E2 proposed by van Rijn et al. (van Rijn et al. 1994, J Virol 68, 3934–42) and confi rmed their expression 
by immunostaining of plasmid-transfected SK6 cells. No equivalents for the antigenic units B/C and A were found on E2 
of BVDVII. This indicates major structural differences in E2. However, the immunodominant BVDVII domain A, contain-
ing epitopes with essential amino acids between position 760–764, showed to be dependent on the presence of the region 
defi ned by amino acids 684 to 796. As for the A domain of CSFV, the BVDVII A-like domain seemed to function as a 
separate unit. These combined domains in E2 proved to be the only combination which was functional in viral background 
of CSFV C-strain. The fi tness of this virus (vfl c36BVDVII 684–796) seemed to be reduced compared to vfl c9 (with the complete 
antigenic region of BVDVII).
Keywords: classical swine fever virus, bovine viral diarrhoea virus, transient expression, chimeric viruses
Introduction
Classical swine fever virus (CSFV) is a small enveloped positive-strand RNA virus classifi ed in the 
genus Pestivirus, which also comprises bovine viral diarrhea virus (BVDV) and border disease virus 
(BDV). Together with the genera Flavivirus and Hepacivirus, it forms the family Flaviviridae (Heinz 
et al. 2000). The genomic RNA of approximately 12.3 kb contains a single long open reading frame 
(ORF) encoding 3898 amino acids fl anked by 5' and 3' non-translated regions (NTR). The translated 
polyprotein is processed by viral as well as cellular proteases to yield the mature viral proteins 
(Meyers and Thiel, 1996). The envelope of pestiviruses contains three glycoproteins, Erns, E1, and 
E2 (Thiel et al. 1991). In infected animals antibodies are raised against Erns and E2 (Wensvoort et al. 
1990; Kwang et al. 1992). Up till now, no antibodies have been detected against E1 in infected 
animals.
The E2 glycoprotein has a molecular mass of 51 to 54 kDa and carries four potential N-glycosylation 
sites (Moormann et al. 1990). Though the E2 glycoprotein forms homodimers as well, the E1-E2 het-
erodimer is the major component of mature virions (Branza-Nichita et al. 2001). The E2 protein is also 
the major target for virus neutralising antibodies.
Hulst et al. (Hulst and Moormann, 1997) demonstrated that CSFV E2 and Erns proteins inhibit 
BVDV and CSFV infection. In cell culture this is achieved by binding of the CSFV E2 and Erns proteins 
to the BVDV-E2 and CSFV-E2 and Erns receptors, suggesting that there is homology in the binding 
sites between the E2 proteins and the Erns proteins of both viruses. In BVDV the putative receptor for 
E2 has been identifi ed as a 50 kDa cell surface protein (Xue et al. 1997) and was identifi ed as CD46bov 
(Maurer et al. 2004). The interaction between E2 and its receptor is reversible, but the interaction 
between Erns and its receptor, heparan-sulphate, is irreversible. These data suggest that during BVDV 
cell attachment and entry the virus must fi rst bind to heparan-sulphate. Then it searches the host cell 
membrane for the E2 receptor. It was suggested that only if the E2 receptor binding domain binds to 
its receptor, receptor mediated endocytosis is initiated (Schelp et al. 2000; Hulst, Krey et al. 2005). 
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Like the E1 glycoprotein the E2 glycoprotein has 
a C-terminal trans-membrane region (TMR). The 
TMR keeps both proteins in the ER where it accu-
mulates in the absence of viral budding (Kohl et al. 
2004). Erns lacks a trans-membrane spanning 
domain but results from co- and sequential 
immunoprecipitation studies between E2 and Erns 
suggested that Erns is attached to the pestivirus 
envelope through a direct interaction with E2 
(Lazar et al. 2003). Recently, it was demonstrated 
that Erns does have an unusual type of membrane 
anchor (Fetzer et al. 2005), which is anchored in 
plane in the membrane by an amphipathic helix 
(Tews and Meyers, 2007).
The E2 glycoprotein of CSFV and BVDV have 
been subject for mutagenesis studies (van Rijn 
et al. 1992; van Rijn et al. 1993; van Rijn et al. 
1994; Paton et al. 2000; Deregt et al. 1998b). In 
some of these studies it was shown that mAbs 
specifi c for antigenic sites bind to the amino half 
of the E2 glycoprotein. Based on the studies for 
E2 of CSFV, an antigenic structure (see Fig. 1), 
in which two antigenic structural units, the non-
conserved domains B/C and the conserved A 
domain, were proposed. For BVDV-E2, the 
location of the epitopes and their conformational 
requirements are somewhat similar to those 
reported for the non-conserved domains B and C 
for E2 of CSF (Paton et al. 1997, although the 
BVDV antigenic site extends further from the 
N-terminus. So far, no equivalent for BVDV has 
been found of the highly conserved domain A of 
CSFV. The absence of a fully conserved antigenic 
site in E2 or BVDV may simply refl ect local 
variation in amino acids sequences between 
strains, but alternatively, the highly conserved 
antigenic domain A of CSFV may have no coun-
terpart in BVDV due to more substantial differ-
ences in the three dimensional structure of the 
proteins. A major difference between the N-ter-
mini of the E2 proteins of BVDV and CSFV is 
an additional two cysteine residues (cysteine 751 
and 798) in BVDV. Although neither of these were 
shown to be  essential for mAb binding, their 
presence may still be an indication of signifi cant 
topographical differences.
In this paper we describe chimeric CSFV/
BVDV E2 expression constructs to study the role 
of the extra cysteine residues for antigenicity 
and functionality within E2. This could be impor-
tant for the development of CSFV and BVDV 
vaccines.
Materials and Methods
Cells and viruses
Swine kidney cell line SK-6 (Kasza et al. 1972) 
was maintained as described previously (van 
Gennip et al. 2000).
Swine kidney cells (SK6) were grown in Eagle’s 
basal medium containing 5% fetal bovine serum, 
glutamine (0.3 mg/ml), and the antibiotics penicil-
lin (200 U/ml), streptomycin (0.2 mg/ml), and 
mycostatin (100 U/ml). Fetal bovine serum was 
tested for the absence of BVDV and BVDV anti-
bodies. SK-6 cells expressing bacteriophage T7 
RNA polymerase (SK6.T7) (van Gennip et al. 
Figure 1. Schematic representation of hybrid CSFV/BVDV E2 con-
structs. Amino acid positions, restriction sites, cysteines, and 
exchanged regions are indicated. The drawing below represents the 
CSFV envelope glycoprotein E2. Proposed signal peptide transmem-
brane region and internal hydrophobic region are shown as closed 
bars. Position of MAR mutations and cysteines are indicated by open 
and closed circles, respectively. Proposed disulphide bonds in the 
N-terminal half of E2 are shown. The location of the antigenic domains 
are indicated by open bars in the lower part. Positions with respect to 
the amino acid sequence of CSFV strain C are shown at the bottom.
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1999) were grown in the same medium supple-
mented with 12.5 times diluted histidinol stock 
solution (125 mM histidinol in 100 mM HEPES). 
Foetal bovine epithelial (FBE) cells were grown 
in Earle’s MEM supplemented as described for 
SK6 cells.
Recombinant C-strain viruses were grown as 
described (van Gennip et al. 2000) in Eagle’s basal 
medium. Virus stocks were prepared by passaging 
the virus three times on SK6 cells. BVDV strain 
5250 of porcine origin (Wensvoort et al. 1989) was 
biologically cloned three times by end point 
dilution on bovine turbinate (BT) cells and was 
also grown on SK6 cells as described above.
Cloning and mutagenesis 
of C-strain E2
A BamHI/fi lled-in fragment containing E2 gene of 
plasmid pPRC34 (van Rijn et al. 1992) was cloned 
in a fi lled-in NdeI digested pUC19M (transformer 
site-directed mutagenesis kit; Clontech), resulting 
in plasmid pPRKc19.
Five different restriction sites were introduced 
in C-strain E2 of plasmid pPRKc19 using the 
Transformer site directed mutagenesis kit 
(Clontech) with primers (p866–p870) defi ned in 
Table 1 and LacZ repair primer p962 to achieve 
blue/white screening. Therefore, the primers were 
annealed with 130 ng plasmid pPRKc19 in anneal-
ing buffer (Clontech) by incubating at 100 °C for 
3 min. and direct placing on ice. Then, T4 DNA 
polymerase (2–4 U; Clontech) and T4 DNA ligase 
(4–6 U; Clontech) were added and the mutagenesis 
reaction was carried out in synthesis buffer 
(Clontech) during 2 hr at 37 °C and the reaction 
was stopped during 5 min. at 70 °C. The reaction 
was phenol/chloroform purified and ethanol 
precipitated. Half of the reaction was transformed 
to SEM-competent (Inoue et al. 1990) E.coli 
BMH71-18 mutS cells (Clontech) and different 
dilutions were plated on agar plates containing 
Amp, Tet, IPTG and X-gal. After incubation o/n 
blue colonies were analyzed for introduction of 
restriction sites. All plasmids were sequenced to 
confi rm the introduced sites and sequence of E2. 
The E2 gene was SpeI/Afl II cloned in an expression 
vector pEVhisD11 (Peeters et al. 1992), in which 
the BglII site was destroyed. This plasmid was 
designated pPRKc22. Expression of C-strain E2 
was confi rmed by transfection of SK6 cells and an 
immuno peroxidase monolayer assay (IPMA) 
(Wensvoort et al. 1986) using a panel of monoclo-
nal antibodies.
Construction of chimeric CSFV/
BVDV-E2 expression constructs
The SpeI-SalI fragment of pPRKc22 was cloned 
in expression vector pPRc83, which contains the 
structural genes of CSFV strain C (Npro-C-ERNS-
E1-E2, amino acids 5 to 1063 of the sequence of 
CSFV strain C) (Moormann et al. 1996), resulting 
in plasmid pPRKc39. DNA fragments coding for 
targeted regions were derived by PCR from pPRK-
bvd77 (van Rijn et al. 1997), containing BVDV 
Table 1. Primers used for mutagenesis and PCR.
Primer Introduced restriction site (posa) Sequence
P866 HindIII (nt position 2513) cttccaggtggtggtcaagcttccggccccaagtag
P867 NruI (nt position 2609) tactgaccacattaatcgcgatgactttaaaggaacc
P868 BstBI (nt position 2759) cccttaacaacaggattcgaatcaaacgggcacag
P869 FspI (nt position 2857) ttgggctcactgctgcgcactctatgacacc
P870 BglII (nt position 2965) aacttacaatagaatagatcttcattttccac
P962 LacZ-repair cgtcgtgactgggaaaaccctg
P955 SpeI tgtggctgatactagtaacgggggcaca
P956 BglII gcattcatggagatcttcccctatac
P1116 (NruI-rev) NruI gcacgtcgcgattattttcaagtctttcc
P1115 (BstBI-rev) BstBI tactggtttcgaatcacaagggcagagtccaaa
P1110 (NruI-forw) NruI aaaatattcgcgacgtgcacaagggaagagagg
P1112 (BstBI-rev) BstBI) ccttgtgattcgaaaccagtaataaagggcaaa
aposition of introduced restriction site at position in full-length C-strain sequence (EMBL database no. Z46258).
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E2 from strain 5250, with Vent polymerase by 
using pairs of oligonucleotide primers listed in 
Table 1. Different restriction sites are incorporated 
at 5’ ends of the primers (underlined). PCR frag-
ments were inserted with the appropriate restriction 
sites in plasmid pPRKc22 or pPRKc39 to produce 
a series of chimeric constructs: pPRKh21 (p955/
p1116), pPRKh22 (p955/p1115), pPRKh23 (p1110/
p956), pPRKh24 (p1112/p956), and pPRKh25 
(p1110/p1115), which are depicted in Figure 2. 
Plasmid pPRKh26 was constructed by subcloning 
the BstBI/SalI fragment from plasmid pPRKh24 
into the BstBI and SalI sites of pPRKh21. All con-
structs were sequenced as above to ensure that the 
Figure 2. Proposed antigenic structure of CSFV envelope glycoprotein E2. Charged amino acids (D, E, K, R, H), cysteines, MAR mutations 
(•), proposed disulphide bonds in the N-terminal half of E2, antigenic domains, and glycosylation groups are indicated (van Rijn et al. 1994).
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E2 gene segments were in the correct reading frame 
and to confi rm the introduced sequence.
Transient expression of chimeric 
CSFV/BVDV constructs
All plasmid DNA was purified by columns 
(Qiagen) as specified by the manufacturer. 
Expression of the chimeric constructs was studied 
by transfection of plasmids on SK6 cells, 
essentially as described (van Rijn et al. 1993; van 
Rijn et al. 1994). For transfection of plasmid 
DNA, 200 ng of Qiagen purifi ed DNA was directly 
diluted in 25 ul of optimemI and mixed with 1 ug 
lipofectamine (GIBCO) diluted in 25 ul optimemI. 
After incubation at room temperature for 15 min, 
transfection was performed on subconfuent 
monolayers of SK-6 cells cells grown in 15 mm 
wells (Costar). Wells were washed once with 
optimemI , and 0.25 ml optimemI was added, 
followed by the transfection mixture. After 
transfection, the monolayers were incubated for 
5 h at 37 °C. Then the transfection mix was 
replaced with 1 ml of Eagle’s basal medium with 
5% fetal bovine serum. Monolayers were fi xed 
with cold (4 °C) methanol/acetone (1:1) and 
immunostained in an IPMA (Wensvoort et al. 
1986) with mAbs 24 h after transfection.
Construction of CSFV/BVDV-E2 
chimeric mutants based on C-strain 
CSFV full-length cDNA
The ClaI/BglII fragment of plasmids pPRKh21, 
pPRKh22 and pPRKh26 containing the chimeric 
CSFV/BVDV-E2 genes were inserted in 
pPRKfl c133 (Moormann et al. 1996), resulting in 
full-length plasmids pPRKfl c35, pPRKfl c36 and 
pPRKflc40. Plasmid pPRKflc35BVDVII 684–745 
contains a chimeric E2 in a full-length cDNA of 
CSFV. The chimeric BVDV/CSFV-E2 of plasmid 
pPRKfl c35BVDVII 684–745 comprises the BVDVII-E2 
sequence corresponding to amino acids 684 to 745 
(Fig. 2). Plasmid pPRKfl c36BVDVII 684–796 harbours 
the BVDVII-E2 sequence between the SpeI and 
BstBI site corresponding to amino acid 684 to 796 
and plasmid pPRKfl c40BVDVII 684–745, 797–864 harbours 
the BVDVII-E2 sequence between the SpeI and 
NruI (aa. 684–745) site and again from the BstBI 
to the BglII site (aa. 797–864).
The NgoMIV/BglII fragment of plasmids 
pPRKh23, pPRKh24 and pPRKh25 containing the 
chimeric CSFV/BVDV-E2 genes were inserted in 
pPRKflc133, resulting in full-length plasmids 
pPRKfl c37BVDVII 746–864, pPRKfl c38BVDVII 797–864 
and  pPRKf lc39 B V D V I I  7 4 6 – 7 9 6 .  P l a smid 
pPRKfl c37BVDVII 746–864 harbours the BVDVII-E2 
sequence between the NruI and BglII site corre-
sponding to amino acid 746 to 864. Plasmid 
pPRKfl c38BVDVII 797–864 harbours the BVDVII-E2 
sequence between the BstBI and BglII site corre-
sponding to amino acids 797–864). Plasmid 
pPRKfl c39BVDVII 746–796 harbours the BVDVII-E2 
sequence between the NruI and BstBI site corre-
sponding to amino acids 746 to 796).
Recovery of chimeric 
CSF/BVD viruses
Plasmids pPRKfl c35-40 were purifi ed on columns 
(Qiagen) and linearized with XbaI. The plasmid 
DNA’s were extracted with phenol-chloroform, 
precipitated with ethanol, and dissolved in water. 
Linearized plasmids (200 ng) were transfected in 
duplicate to SK6.T7 cells grown in 2 cm2 wells 
as described (van Gennip et al. 1999). Culture 
media were collected at 4 days post transfection 
and the monolayers were immunostained with 
Mab C5 (Wensvoort, 1989a) for C-strain Erns 
expression. Media collected from monolayers in 
which expression was observed were applied on 
fresh monolayers of SK6 cells to determine the 
presence of infectious virus. Duplicate transfected 
monolayers were passaged repeatedly to support 
virus growth.
Analysis of chimeric viruses
Supernatants originating from subsequent passages 
from virus vfl c36BVDVII 684–796 were subjected to 
virus titer determination in a plaque assay (Hulst 
et al.  2001). Selected supernatants from 
vfl c36BVDVII 684–796 from passage P8 and P16 were 
subjected to monoclonal antibody typing using 
Mabs C5 specifi c for Erns of CSFV strain C (1:1000; 
(Wensvoort, 1989a), Mab WB166 specifi c for 
BVDV-E2 (1:500 (Paton et al. 1992) and Mab V3 
specifi c for domain A of E2 (1:2000; (Wensvoort 
et al. 1986). Therefore, supernatants from these 
passages were infected on SK6 cells in 10-fold 
dilutions for 90 min. at 37 °C. Two days after 
infection, cells were fi xed with methanol-acetone 
(1:1) and subjected to an IPMA (Wensvoort 
et al. 1986).
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The region of vFlc36BVDVII 684–796 harbouring 
the chimeric E2 gene was RT-PCR amplifi ed. Total 
RNA of SK6 cells infected with the respective 
viruses was isolated with the RNeasy RNA isola-
tion kit (Qiagen). DNA fragments covering the E2 
chimeric region of vFlc36 was amplifi ed by RT-
PCR as described (Widjojoatmodjo et al. 1999) 
and separated on a 1.0% agarose gel in 1xTAE, 
and purifi ed on Costar Spin-X columns. Sequences 
of the purifi ed PCR fragments were determined by 
thermocycle sequencing using the Bigdye termina-
tor ready reaction cycle sequencing kit according 
to the manufacturer’s conditions (Perkin Elmer/
Applied Biosystems Division) with fl anking and 
internal primers and analyzed on a 310 ABI PRISM 
genetic analyzer.
Results
Transient expression of hybrid 
CSFV/BVDV-E2 proteins
The C-terminal half of the E2 protein of CSFV is 
considered to form a membrane-anchored stalk 
that is not involved in the major antigenic sites 
(van Rijn et al. 1994). The N-terminal half of E2 
is predicted to be surface exposed. Several studies 
(van Rijn et al. 1996; Paton et al. 1997) showed 
that only the N-terminal half of E2 is involved in 
the antigenicity.
Starting point for this study is a chimeric E2, in 
which the antigenic region or CSFV was exchanged 
with that of a BVDV type II strain 5250 pPRK-
bvd77; van Gennip et al. 2000. After transient 
expression, this protein could be discriminated 
from C-strain E2 by specifi c BVDV mAbs, indicat-
ing that this protein was correctly folded and 
expressed. Furthermore, this chimeric protein also 
showed to be functional in viral background (van 
Gennip et al. 2000).
To study the role of the region containing two 
extra cysteine residues within the N-terminal half 
in BVDV, a series of chimeric CSFV/BVDV-E2 
expression constructs were constructed in the same 
expression vector as used for pPRKbvd77. The 
chimeric CSFV/BVDV constructs (Fig. 2) were 
defi ned by cysteine residues, based on the struc-
tural model of CSFV-E2 (Fig. 1). These chimeric 
DNA constructs were expressed by transient trans-
fection of SK6 cells and tested for reactivity with 
a panel of mAbs (see Table 2). The mutagenised 
E2 of the C-strain in plasmid pPRKc22 reacted 
with all tested mAbs specifi c for CSFV and not 
with BVDV mAbs. It also reacted with mAb 4-9D4 
raised against a linear epitope, located in the 
C-terminal half of E2 (Yu et al. 1996). This was 
Table 2. Transient expression in SK6 cells with E2 hybrid genes of CSFV strain C and BVDVII strain 5250.
Plasmid CSFV Mabsa BVDV Mabsb Pesti Mabc
domain B/C C A1 A3 D A A B C Unknown C-terminus
Mabs C2 C6 V4 V12 V13 WB 166 BA-2 BA-29 BA-20 Lyon #4 Lyon #5 4-9D4#
pPRKc22 +++ +++ +++ + ++ − − − − − − +
pPRKh21 − − +/−d − − − − − − − − +
pPRKh22 − − ++ − ++ ++ ++ − − ++ ++ +
pPRKh23 − − − − − − − − − − − +
pPRKh24 +/− + − − − − − − − − − +
pPRKh25 − − ++ − − − + − − + − +
pPRKh26 − − − − − − − − − − − +
pPRKbvd77 − − − − + ++ ++ + + ++ ++ +
aMab C2 (1:1000) and C6 (1:1000) specifi cally recognizes epitopes on C-strain E2 (Wensvoort, 1989a); Mab V4 recognizes an epitope in 
domain A of E2 that is conserved among CSFV strains (Wensvoort et al. 1986); Mabs V12 (1:1000) and V13 (1:1000) recognize C-strain 
E2 (Wensvoort, 1989b).
bMab Wb166 (1:500) specifi cally recognizes an epitope, located on an immunodominant domain (exact postion aa. 766) at the N-terminus 
of BVDV E2 (Paton et al. 1992), and is referred to as domain A (Deregt et al. 1998). Mab Lyon #4 (Mab BD204-B11, 1:200) and Lyon #5 
(Mab NY12B1, 1:200) are a gift from Gilles Chappuis (Rhône Mérieux) and are non-defi ned anti BD-BVD (neutralizing). Mabs BA-2, BA-20 
and BA-29 were raised against BVDV type 2 virus (and represent three antigenic regions A, B and C according to competition studies (Deregt 
et al.).
cMab 4-9D4 (1:10) recognizes a linear epitope in the C-terminus of E2 (gift from Lin Fa Wang; (Yu et al. 1996).
d−: negative; +/−: weak staining and less cells positive; +/+++: represents the intensity of staining and number of positive cells.
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considered as a control for expression of E2, since 
this region was not supposed to be affected by the 
mutations in the N-terminal half of E2. The 
chimeric BVDVII/CSFV E2 gene of plasmid 
pPRKbvd77 reacted with all tested BVDV mAbs 
and also with mAb 4-9D4.
The hybrid E2 gene of plasmid pPRKh21, in 
which the N-terminal region (amino acid residues 
684–745; numbering in C-strain polyprotein: see 
also Fig. 3) of CSFV was exchanged with that of 
BVDVII strain 5250 included the two N-terminal 
cysteine residues at amino acid position 693 and 737. 
This resulted in a hybrid E2 gene with 6 cysteine 
residues in the N-terminal half. This protein only 
stained weakly with a mAb V4 (anti domain A), 
and control mAb 4-9D4 (see Table 2). This indi-
cated that the A-domain in this hybrid protein still 
was intact, although the binding seemed to be 
reduced compared to the control. Other epitopes, 
located in domains A3 and D were not recognised 
by their respective mAbs, although the sequences 
for these domains were present in this protein. 
BVDV mAb WB166 and BA-2 did not react with 
this protein because amino acids essential for their 
epitopes are located downstream of the exchanged 
region (760–764 region; numbering in C-strain 
polyprotein; see Figure 3, WB166: Leu 766; (Paton 
et al. 1992). The differences by exchanging this 
region also abrogated binding of the two Lyon 
mAbs #4, #5, BA20 and BA-29. Probably for the 
same reason as for mAb WB166, but the Lyon 
mAbs and BA-20 and BA-29 are undefi ned. We 
can conclude that they do not bind to the region 
(amino acid residues 684–745) of BVDV strain 
5250 in pPRKh21 expressed protein.
When the N-terminal part of the introduced 
BVDV region was extended to aa. 796 (pPRKh22), 
this resulted in a hybrid protein including the two 
extra cysteine residues of BVDV strain 5250 (C751 
and C794; numbering in C-strain polyprotein; see 
Fig. 3). Transfection of pPRKh22 on SK6 cells 
resulted in expression of a hybrid protein which 
was recognized by BVDV mAbs WB166, confi rm-
ing the epitope mapping of Paton et al. (Paton et al. 
1997), Lyon #4 and Lyon #5 (see Table 2). This 
hybrid E2 protein was not recognised by BA-20 
and BA-29. Furthermore, the A and D domains of 
CSFV were recognized by their respective mAbs 
V4 (A) and V13 (D). These results indicate that 
this chimeric protein was correctly folded into a 
BVDV-like domain A (Deregt et al. 1998b) and the 
CSFV domain A.
Mabs selected for the antigenic region did not 
recognize the hybrid E2 protein expressed from 
plasmid pPRKh23, in which the region from aa. 746 
to 864 from BVDVII strain 5250 was introduced. 
Expression of this chimeric protein was confi rmed 
by mAb 4-9D4. Although the epitopes for the anti 
CSFV-E2 mAbs C2 and C6 are defi ned to the B/C 
domain and this domain can function as a separate 
unit (van Rijn et al. 1996) it was not recognized in 
this hybrid E2 protein. The same holds true for anti 
BVDV mAb WB166, which epitope is well defi ned 
(Leu, 766). Probably, the exchanged region does not 
result in the right folding of the E2 hybrid protein. 
The binding of the mAbs Lyon #4, #5, BA-20 and 
C-strain RLACKEDYRY AISSTDEIGL LGAGGLTTTW KEYNHDLQLN DGTVKASCVA  739 
Oregon C24V HLDCKPEYSY AIAKSDRIGL QGAENLTTVW KDYSHGMTLE DTMVIAWCKD  739 
5250 FPECKEGFQY AISKATKIGL LGPESLTTTW H--LPTKKLG GSMVQVWCEG  737 
C-strain GSFKVTALNV VSRRYLASLH KKALPTSVTF ELLFDGT-NP STEEMGDDFR  788 
Oregon C24V GKLTYYARCT RETRYLAILH SRALPTSVVF KKLFEGQGQE DTVEMDDNFE  789 
5250 KDLKILKTCT REERYLVAVH ERALSTSAEF MQISDGKLGP SVIDMPDDFE  787 
C-strain SGLCPFDTSP VVKGKYNTTL LNGSAFYLVC PIGWTGVIEC TAVSPTTLRT  838 
Oregon C24V FGLCPCDAKP IVRGTYNTTL LNGPAFQMVC PIGWTGTVSC MLANRDTLDT  839 
5250 FGLCPCDSKP VIKGKFNASL LNGPAFQMVC PQGWTGRIEC TPANQDTLDT  837 
668LDENEVTTTVCDMRHPFPKDRRFTKVVEniarts-C
768LDEGLTKQTICGQRYPFPRSRRYTRVVAV42CnogerO
5250    TVVRTYRRTT PFQRRRWCVS AKMIGEDL 865 
Figure 3. Comparison of the amino acid sequences of E2 proteins from position 690 to 865 of CSFV-strain C (accession number Z46258), 
BVDV strain Oregon C24V (accession number AF091605) and BVDV type II strain 5250 (acc. Number Y12168). The positions of amino 
acids (shaded grey) are based on those of CSFV strain C (Moormann et al. 1996). C693 CSFV = C696 Oregon, C737 CSFV = C740 Oregon, 
C751 Oregon (extra), C792 CSFV = C796 Oregon, C798 Oregon (extra), C818 CSFV = C822 Oregon, C828 CSFV = C832 Oregon, C856 
CSFV = C860 Oregon.
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BA-29 are also disturbed in this hybrid protein. 
When the N-terminal region of CSFV in plasmid 
pPRKh23 was extended to aa. 796, resulting in 
plasmid pPRKh24, this resulted in the repair, 
although weaker than the control, of mAb C2 and 
C6, located in the B/C domain of CSFV-E2. This 
confi rms the hypothesis that the extra cysteines of 
BVDV (C751 and C798) in pPRKh23 disturbs cor-
rect folding and exposure of the B/C domain of 
CSFV. Mabs WB166, V3 and Lyon mAbs #4 and 5 
did not bind to this hybrid E2 protein because of the 
absence of their epitopes. Mabs BA-20 and BA-29 
also did not recognise this hybrid E2 protein.
To see whether we could locate some of the 
non-defi ned mAbs Lyon #4 and #5, the region from 
BVDVII strain 5250 from aa. 746 to 796 was 
exchanged with that of CSFV, resulting in plasmid 
pPRKh25. This hybrid E2 protein was recognized 
by Lyon mAb #4 and BA-2, and not by the other 
anti BVDV mAbs WB166, Lyon #5, BA20 and 
BA-29. Binding of mAbs WB166 and Lyon #5 
seemed to be dependent on the presence of the 
N-terminal region from aa. 684 to 745 for binding, 
which was also the case in the hybrid E2 protein 
expressed from plasmid pPRKh23. Mabs C2 and 
C6 did not bind to the B/C domain of hybrid E2 
protein expressed from plasmid pPRKh25, which 
is a similar result as found for plasmid pPRKh23. 
The B/C domain seems to be disturbed by the 
introduction of the extra cysteine residues in the 
BVDV sequence. The remaining A domain of 
CSFV still was able to bind mAb V4. This result 
was also similar as for hybrid E2 protein expressed 
from plasmid pPRKh22.
The hybrid E2 protein, in which only aa. 746 to 
796 of the N-terminal half of E2 consists of CSFV 
sequence, expressed from plasmid pPRKh26, was 
not recognized by any of the selected mAbs within 
the antigenic region. Protein expression 
was confi rmed by mAb 4-9D4, located in the 
C-terminus of E2.
Construction and transfection 
of full-length DNA’s with hybrid 
CSFV/BVDV-E2 proteins
The hybrid CSFV/BVDV E2 genes, which expressed 
proteins were tested for their capability to bind 
mAbs, were inserted in the full-length copy of the 
C-strain (Moormann et al. 1996), resulting in a series 
of full-length CSFV/BVDV chimeric DNA 
constructs to study whether these proteins were 
functional in viral background. Linearized full-
length DNA’s of pPRKflc35-40, together with 
control full-length DNA’s of pPRKfl c9 (van Gennip 
et al. 2002), with the antigenic region of BVDVII 
strain 5250 from plasmid pPRKbvd77, and the 
C-strain full-length DNA pPRKfl c12, with mutated 
E2 from plasmid pPRKc22, were transfected in 
duplicate on SK6.T7 cells. Four days after transfec-
tion, supernatants were removed and stored for 
further analysis. The monolayers were fi xed and 
immunostained with an anti-CSFV Erns mAb C5. 
For every construct, expression of Erns was observed. 
The duplicate wells were trypsinized and pas-
saged to support virus growth. Passage 2 (p2) was 
tested in an IPMA using mAb C5. As shown in 
table 3, only SK6.T7 cells transfected with 
Table 3. Results after immunostaining of SK6.T7 cells transfected with full-length CSFV/BVDV DNA’s from serial 
passages.
Passage number1
Full-length DNA Expression plasmid p1 p2 p5
pPRKfl c12 (C-strain) pPRKc22 ++++ ++++ ++++
PPRKfl c9BVDVII 684–864 pPRKbvd77 ++ +++ +++
pPRKfl c35BVDVII 684–745 pPRKh21 + − −
pPRKfl c36BVDVII 684–796 pPRKh22 + ++ ++
pPRKfl c37BVDVII 746–864 pPRKh23 + − −
pPRKfl c38BVDVII 797–864 pPRKh24 + + −
pPRKfl c39BVDVII 746–796 pPRKh25 + + −
pPRKfl c40BVDVII 684–745, 797–864 pPRKh26 + + −
1Passage number of transfected SK6.T7 cells. Duplicate monolayers of passaged SK6.T7 cells, plated in 2 cm2 wells, were immunostained 
with mAb C5 for C-strain Erns expression.
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pPRKfl c36BVDVII 684–796 showed very strong staining 
over the whole monolayer, similar to monolayers 
of pPRKfl c9-transfected SK6.T7 cells, indicating 
viral replication. The monolayers of SK6.T7 cells 
(p2) transfected with pPRKflc38BVDVII 797–864, 
pPRKfl c39BVDVII 746–796 and pPRKfl c40BVDVII 684–745, 
797–864 only showed single positive cells (1–5 cells/
cm2) in 3 out of four tested wells. This indicated that 
replication of RNA occurs, albeit at a low level. 
Monolayers of SK6.T7 cells (p2) transfected with 
pPRKfl c35BVDVII 684–745 and pPRKfl c37BVDVII 746–864 
did not show any positive cells after immunostain-
ing, indicating that this RNA was not able to repli-
cate or at a non-detectable level. Supernatants from 
p2 were tested in a plaque assay. Besides the 
controls, only the supernatant from pPRKfl c36BVDVII 
684–796 -transfected SK6.T7 cells contained infectious 
virus. This confi rmed that no infectious virus, or at 
a non-detectable level, was generated from SK6.T7 
cells transfected with the other full-length DNA’s. 
Passaged transfected cells (p5) was also tested and 
were found to be negative for any of these contructs, 
indicating that these replicons are diluted by 
passaging and eventually will be absent (Table 3).
Analysis of chimeric virus 
vfl c36BVDVII 684–796
Supernatants derived from p5 of SK6.T7 cells 
transfected with pPRKfl c36BVDVII 684–796 had only 
virus titers of 102.6 pfu/ml, whereas supernatants 
of pPRKflc9-transfected SK6.T7 cells (p5) 
already had a virus titer of 105.5 pfu/ml, and 106.6 
pfu/ml for C-strain, which are average virus titers 
expected after 5 passages. The virus titer did not 
increase after further passaging. Supernatant from 
p16 had the same virus titer (102.6 pfu/ml), indi-
cating that the this chimeric virus was somehow 
hampered in virus replication, compared to 
viruses vfl c9 and vfl c12. Virus vfl c36BVDVII 684–796 
obtained from p5 and p16 was still able to bind 
mAbs V3/4 and WB166, indicating that the hybrid 
CSFV/BVDV E2 protein still exposed the 
domains important for binding these mAbs. 
Analysis of sequences derived from RT-PCR 
amplicons (p8) of the antigenic region of E2 
showed no differences, which does not exclude 
mutations elsewhere.
Discussion
The envelope glycoprotein E2 of BVDV has two 
extra cysteine residues compared to CSFV-E2. 
In this report, we studied the infl uence of these two 
cysteines on mAb binding and functionality in viral 
background through reverse genetics to look for 
similarities or differences between CSFV and 
BVDV. Therefore, a set of interchimeric BVDVII/
CSFV E2 proteins were tested for reactivity with 
a panel of BVDV and CSFV mAbs in a transient 
expression system on SK6 cells. This system has 
already been used successfully for epitope mapping 
studies of E2 of CSFV (van Rijn et al. 1994; van 
Rijn et al. 1993; van Rijn et al. 1992).
Transfection studies with chimeric E2 con-
structs of BVDV and CSFV showed that the 
binding of mAbs was the least affected in E2 
expressed from pPRKh22, with the proposed “A” 
like domain of BVDV (Deregt et al. 1998b; 
Deregt et al. 1998a) and the A domain of CSFV 
(van Rijn et al. 1994). The A domain of CSFV is 
the most stable domain in chimeric background. 
All chimeric constructs (pPRKh21, 22 and 25) 
containing an A domain were recognised by a 
mAb specifi c for this domain. Binding of mAb 
V4 was reduced when the B/C domain of CSFV 
was exchanged with that of BVDVII. This was 
an unexpected fi nding since no extra cysteines 
were introduced. Probably, this region imposes a 
certain structure in E2, thereby affecting the A 
domain (Paton et al. 1997).
The B/C domain of CSFV appears to be less 
stable in chimeric background. Binding of mAbs 
specifi c for this domain did not recognise their 
epitopes in pPRKh23 and 25. In both cases, two 
extra cysteine residues were introduced from 
BVDVII. This suggests that introduction the two 
extra cysteines (Cys 751 and Cys798) disturb cor-
rect folding and expression of the B/C domain of 
CSFV.
The BVDV “A”-like domain (Deregt et al. 
1998b), which epitopes are located in an immuno-
dominant region from aa 760–764 is dependent on 
the presence of the BVDV equivalent of the B/C 
domain of CSFV. Mabs WB166 and BA-2, which 
epitopes are located in the 760–764 region, and 
mAb Lyon#4 and #5 recognised chimeric E2 from 
plasmid pPRKh22. MAb BA2 and Lyon #4 also 
recognised the smallest exchanged region, with the 
two extra cysteine residues from BVDV, between 
the B/C and A domain of CSFV. Although this 
region was also present in pPRKh23, it was not 
recognised by Lyon#4 and BA-2, indicating 
structural infl uences of the region downstream the 
epitopes of BA-2 and Lyon#4.
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None of the chimeric E2 proteins were recognised 
by mAbs BA-20 and BA-29. These mAbs only 
recognised native E2 of BVDVII in pPRKbvd77. 
MAbs BA20 and BA-29 were raised against BVD-
VII virus followed by peptides located in the 
N-terminus of E2 (Deregt et al. 1998b) and accord-
ing to competition studies bind to different domains 
of BVDVII. We were not able to confi rm these 
fi ndings. Since these mAbs did not recognise any 
of the chimeric E2 proteins we were also not able 
to map these mAbs. We concluded from these 
results that the proposed B and C domain Mabs 
(BA-29 and BA-20 respectively) seem to be depen-
dent on the presence of the total antigenic region 
of BVDVII.
The obtained results from the transfection stud-
ies with the chimeric E2 CSFV /BVDVII con-
structs indicate that there are major structural 
differences in E2 of CSFV compared to that of 
BVDVII. We found no equivalent for the A and 
B/C domain of CSFV, although we might not have 
the right tools (e.g. more mAbs). Recently, van 
Rijn discovered a common neutralizing epitope on 
E2 of different pestiviruses, located in the B 
domain of E2, indicating that similarities are pres-
ent between different pestiviruses (van Rijn, 2007). 
This and other studies (Deregt et al. 1998b; Paton 
et al. 1992) strongly support the opinion that there 
is an immunodominant domain A (Deregt et al. 
1998b) which is located between the 760–764 
region and the importance of aa 761 in BVDV. The 
majority of BVDV epitopes have been mapped for 
this particular amino acid residue in the 760–764 
region. Interestingly, no escape mutants have been 
mapped in this region for CSFV, indicating that 
this region does not have the same importance for 
CSFV.
The role of the extra two cysteine residues 
remain unclear, although some infl uence of the 
cysteines was observed in hybrid E2 proteins it 
cannot be excluded that this is the result of the 
introduction of the BVDV region harbouring the 
epitopes. Paton et al. (Paton et al. 1997) already 
showed that binding of mAb WB166 is only depen-
dent on the presence of an intact pair of the fi rst 
two cysteines.
It is possible that the reduction in some MAb 
binding with chimeric E2 proteins could be due to 
misfolding of the E2 protein due to different inter-
actions of sulfhydryl groups or to simple degradation 
of the E2 protein. Even if misfolding occurred, 
eukaryotic cells have a system for retaining 
misfolded proteins in the endoplasmic reticulum 
and cycle these defective proteins back to the 
ubiquitin-proteosome system for hydrolysis 
(Plemper and Wolf, 1999). Since Mab reactive (and 
therefore intact) E2 protein could be identifi ed, it 
is likely that any reduction in reactivity of Mabs 
with the chimeric E2 proteins in these experiments 
was not the result of drastically misfolded or 
degraded protein. To circumvent the problems with 
incorrect folding by mispairing of cysteine resi-
dues, it would be feasible to make E2 chimeras 
between two BVDV strains (e.g. BVDVI and 
BVDVII). Thereby the cysteine distribution 
remains intact within these chimeric E2’s and 
conformational changes due to incorrect folding 
seem less probable, although the primary structure 
of a protein is determined by its amino acid 
sequence.
We were able to rescue only one virus (vfl c36) 
through reverse genetics which had a functional 
chimeric E2. This virus contained a chimeric E2 
with the “A” like domain of BVDVII (Deregt et al. 
1998b) and the A-domain of CSFV (van Rijn et al. 
1994). This chimeric E2 also bound to most of the 
mAbs located in the two domains. The B/C domain 
and A domain of CSFV are also able to function 
as separate antigenic units which are recognised 
by mAbs and are able to elicit a protective antibody 
response in pigs (van Rijn et al. 1999; van Gennip 
et al. 2002). Further studies should be performed 
to test the protective capacity of this possible 
marker vaccine vfl c36. The fi tness of this virus 
seemed to be reduced compared to vfl c9 (with the 
complete antigenic region of BVDVII). Virus titers 
reached maximum values of titers of 102.6 pfu/ml 
compared to 105.5 pfu/ml for vfl c9 and 106.6 pfu/ml 
for parent vaccine C-strain. Furthermore, virus 
vfl c36 did not grow on bovine cells (data not 
shown). This was not very surprising, since vfl c9 
also showed reduced infectivity on FBE cells (van 
Gennip et al. 2000). The functionality of this chi-
meric E2 in vfl c36 seems to be reduced, which is 
most likely caused by conformational changes. 
These changes could affect functional domains 
involved in interaction with cellular receptors. We 
were not able to rescue detectable amounts of 
infectious viruses from any the other chimeric 
DNA constructs, probably due to non-functional 
chimeric E2’s in these viruses. For some of the 
chimeric constructs, RNA replication and transla-
tion could be detected in SK6.T7 cells indicating 
autonomous replication, but at a very low level. 
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Due to dilution by passaging transfected SK6.T7 
cells the number of positive immunostained cells 
decreased to undetectable levels. For further char-
acterization of these non-viable viruses they should 
be trans-complemented through a E2-complement-
ing SK6 cell line, which were already successfully 
used in another study to rescue defective RNA’s 
with deleted parts of E2 (van Gennip et al. 
2002).
In a recent study from Wehrle et al. they showed 
that a chimeric virus vRiems-ABC-Gif (Wehrle 
et al. 2007), which is similar in concept to our Flc9 
(van Gennip et al. 2000), also had similar marker 
vaccine properties compared to our Flc9 (de Smit 
et al. 2001). Since the only difference is the back-
ground of these viruses this implies a broad use of 
these kind of strategies. Additionally, in accordance 
to their study, we also found that the B/C domain 
could be exchanged resulting in a infectious virus 
Flc36. Virus titers of Flc36BVDVII 684–796 were lower 
(102.6 pfu/ml) compared to that of vRiems-BC-Gif 
104.3 TCID50/ml. However, our Flc36BVDVII 684–796 
contains about fi fty amino acids more than vRiems-
B/C-Gif, including the two extra cysteines from 
the BVDV 5250 strain. Their vRiems-B/C-Gif 
resembles our vfl c35BVDVII 684–745, which in our 
hands did not result in a viable virus. Small differ-
ences could account for these results, but other 
unknown factors can also attribute to our fi ndings. 
Our study also confirmed their findings with 
respect to the A domain exchange in vRiems-
A-Gif, which behaved like a replicon. In their 
hands, this replicon could not be trans-complemented 
in an E2 expressing cell line, indicating misfolding 
or incorrect E1-E2 heterodimerization, which is a 
prerequisite for effi cient cell entry of the virus 
particle (Wang et al. 2004).
The results presented here show that the immu-
nodominant domain “A” in BVDVII together with 
the A-domain from CSFV forms a functional E2 
in viral background, although with reduced fi tness. 
The major structural differences, including the two 
extra cysteine residues in BVDV, between CSFV 
and BVDV are probably responsible for the non-
functional E2 proteins. More structural knowledge 
of both CSFV and BVDV E2 is necessary to open 
the possibility to develop mutant viruses with 
chimeric E2 protein. The general conformational 
stability of the BVDV “A” domain and the CSFV 
A-domain, however, suggest possible targets in the 
E2 protein for the development of effective and 
specifi c marker vaccines.
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